Vmbook Online ordering

Trovagene Inc

**Company Name:** Trovagene, Inc.

**Ticker Symbol:** TROV (NASDAQ)

**Industry:** Biotechnology

**Headquarters:** San Diego, California, USA

**Website:** https://www.trovagene.com/

**Business Description:**

Trovagene is a biotechnology company focused on developing and commercializing molecular diagnostics and targeted therapeutics for cancer. The company's core technology platform is its proprietary TrovaGene platform, which uses proprietary methods to analyze gene expression patterns to identify biomarkers and develop diagnostic and therapeutic products.

**Key Products and Services:**

* **Provista®:** A molecular diagnostic test that detects and measures gene expression levels to assess the risk of breast cancer recurrence.

* **OncoTect®:** A molecular diagnostic test that detects and measures gene expression levels to guide treatment decisions in patients with advanced solid tumors.

* **TVGN-489:** A small molecule inhibitor targeting the GSK-3 beta protein, which is being developed for the treatment of solid tumors.

**Financial Information (as of March 31, 2023):**

* **Revenue:** $1.9 million

* **Net Loss:** $10.6 million

* **Total Assets:** $19.1 million

* **Total Liabilities:** $12.3 million

**Market Capitalization:** $36.5 million

**Share Price (as of April 11, 2023):** $0.83

**Key Executives:**

* **Jason I. Sager, Ph.D.:** President and Chief Executive Officer

* **Steven W. Jones, Ph.D.:** Chief Scientific Officer

* **Thomas J. Farrell, Jr.:** Chief Financial Officer

**Recent Developments:**

* In March 2023, Trovagene announced positive results from a Phase 2 clinical trial of TVGN-489 in patients with advanced solid tumors.

* In January 2023, the company received a $1 million grant from the National Cancer Institute to support the development of Provista.

* In December 2022, Trovagene entered into a collaboration agreement with Roche Diagnostics to develop and commercialize a companion diagnostic test for TVGN-489.